Supports the use of 2nd-generation basal-l ike insulins, such as insulin degludec-100 and insulin glargine-300, as they provide stable and prolonged glycaemic control.39 Furthermore, they significantly reduce GV, as evidenced by a decrease in MAGE from 74.9 mg/dL (95% CI, 60.3–97.7) to 64.8 mg/dL (95% CI, 52.0–78.2) (p<0.05) when comparing from insulin degludec + DPP4 inhibitor to insulin degludec + liraglutide, and reduce risk of hypoglycaemia.36 The gene discussed is INS; the disease is Hypoglycemia.